# Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants

> **NCT07570069** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 18 (estimated)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Suzetrigine
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT07570069
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-07
- **Primary completion:** 2026-07-11
- **Final completion:** 2026-07-11
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570069, "Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07570069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*